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OBJECTIVES We sought to test the hypothesis that autoantibodies (Abs) produced against sarcolemmal
Na-K-ATPase play a role in the development of ventricular tachycardia (VT) and cardiac
sudden death in patients with dilated cardiomyopathy (DCM).
BACKGROUND Autoimmunity is one of the mechanisms of pathogenesis of DCM as well as virus infection
and genetic predisposition.
METHODS One hundred patients with DCM and age-matched control subjects (CTL) were screened for
Abs produced against Na-K-ATPase by using enzyme-linked immunosorbent assay.
RESULTS Abs were detected in 26 DCM and 2 CTL patients. Na-K-ATPase activity in the presence
of patient IgG was lower in DCM with Abs than without Abs, but there was no difference
between two groups in CTL. Western blots showed that Abs recognized the alpha subunit
of Na-K-ATPase, and 3H-ouabain bindings in the presence of patient IgG showed that
dissociation constant was higher in DCM with Abs than without Abs. No difference existed
between subjects with regard to age, gender, New York Heart Association functional class,
cardiac function, or neurohormone levels, except for plasma norepinephrine, which was
higher in patients with Abs than without Abs. VTs were more common in patients with Abs
than without Abs, and multiple logistic regression analysis demonstrated that the presence of
Abs, but not plasma norepinephrine, was an independent predictor for the occurrence of VT.
Cardiac sudden death was independently predicted by the presence of Abs, as well as poor
systolic function.
CONCLUSIONS We conclude that there are Abs produced against sarcolemmal Na-K-ATPase in patients
with DCM and that Abs could be responsible for the electrical instability in some
cases. (J Am Coll Cardiol 2002;40:1153–9) © 2002 by the American College of Cardiology
Foundation
Numerous prognostic indicators, including cardiac function
and neurohormonal activation, are reported to be useful in
predicting the long-term prognosis of patients with conges-
tive heart failure (CHF) (1–3). Although these parameters
are helpful in predicting heart failure death, there are few
parameters that predict sudden cardiac death caused by
ventricular arrhythmias. Several predisposing factors for the
development of ventricular arrhythmias in patients with
CHF have been proposed, including autonomic nervous
system imbalance, myocardial ischemia, focal fibrosis,
stretch-activation of ion channels and electrolytes distur-
bance (4). Sarcolemmal Na-K-ATPase activity has been
reported to be decreased in patients with idiopathic dilated
cardiomyopathy (DCM) (5). Preliminary data from our
laboratory have shown that erythrocyte Na-K-ATPase ac-
tivity was decreased and inversely correlated with plasma
norepinephrine in CHF patients with coronary artery dis-
eases. However, in patients with DCM, other circulating
substances, except for plasma norepinephrine or digitalis,
also were suggested as decreasing Na-K-ATPase activity,
which was related to the occurrence of ventricular tachycar-
dias (6).
Autoimmunity, viral infection and genetic predisposition
have been proposed as causes of DCM (7). The hypothesis
that autoimmunity may cause cardiomyopathy is supported
by the improvement in subjective symptoms and hemody-
namics in patients after the removal of autoantibodies (Abs)
by immunoadsorption (8). The use of high-dose immuno-
globulin therapy in patients with myocarditis and acute
cardiomyopathy also supports the role of autoimmunity in
the pathogenesis of cardiomyopathy (9).
In the present study, we tested the hypothesis that Abs
produced against Na-K-ATPase cause a decrease in enzy-
matic activity, increasing the risk of ventricular arrhythmias
and sudden death in patients with DCM who have Abs
produced against Na-K-ATPase.
METHODS
Study patients. We studied 100 patients diagnosed with
DCM based on the World Health Organization/
International Society and Federation of Cardiology Task
Force definition and classification of cardiomyopathies re-
port of 1995 (10). At the time of sample acquisition, all
patients were stable under conventional therapy, including
digitalis, diuretics, angiotensin-converting enzyme inhibi-
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tors, or beta-blockers. Eighty-seven patients underwent
cardiac catheterization, which revealed normal coronary
arteries in all of the patients. Endomyocardial biopsy was
performed in 78 patients and revealed no inflammatory cell
infiltrates or granulomas. Healthy control subjects (n 
100) were matched for gender and age. The study protocol
was approved by an institutional review committee, and all
patients gave written, informed consent to participate in the
present study.
Antigen and substrate. As an antigen used in enzyme-
linked immunosorbent assay (ELISA) and as a substrate
used in enzyme activity measurement, porcine cerebral
cortex Na-K-ATPase was obtained from Sigma Chemical
Co (St. Louis, Missouri). It was dissolved in phosphate-
buffered saline (PBS: 10 mM phosphate, 140 mM NaCl,
pH 7.4) to 2 mg/ml and stocked in80°C until the ELISA
was performed. For the enzyme activity measurement,
porcine cerebral cortex Na-K-ATPase was dissolved in 50
mM histidine buffer (pH 7.2) containing 100 mM NaCl, 10
mM KCl, 3 mM MgCl2 and 1 mM EGTA in the same
concentration. As an antigen used in Western blots and as
a substrate used in radioligand binding assay, human myo-
cardium was obtained at the time of autopsy, all of which
exhibited underlying heart diseases. Cardiac membrane
fractions were prepared as 50,000 g pellet by the previous
methods (11). The final membrane pellet was resuspended
in 50 mM Tris-HCl buffer (pH 7.5) containing 250 mM
sucrose and 1 mM EGTA and stored at 80°C.
Enzyme-linked immunosorbent assay. Ninety-six-well
ELISA plates (Iwaki Glass, Japan) was coated with 50 l of
stocked Na-K-ATPase solution plus 0.5% gelatin. Blocking
was performed by PBS supplemented with 3% bovine serum
albumin and 0.1% Tween-20. Fifty microliters of each
patient’s serum, diluted from 1:20 to 1:160, were added to
the microtiter plates and incubated overnight at 4°C. After
washing, a peroxidase-conjugated goat anti-human IgG
(H  L) antibody (1:1000 dilution, Biosource, Camarillo,
California) was added and allowed to react for 1 h. After
washing, the bound peroxidase-conjugated antibody was
detected by incubating the plates for 1 h with orthophe-
nylenediamine dihydrochloride (Organon Teknika, West
Chester, Pennsylvania). Sulfuric acid (2.5 M) was added to
stop the reaction, and the optical density was read at 492 nm
in a microtiter reader with a positive finding defined as an
optical density that was 2.5 times the background density
(12).
Functional enzyme activity measurement with purified
IgG. The IgG purification from patients’ serum was per-
formed by protein A-agarose methods using the Affi-Gel
Protein-A MAPS II Kit (Bio-Rad Laboratories, Hercules,
California). One microgram of purified IgG was added to
50 l of the stocked Na-K-ATPase solution with 3 mM
ATP. For each sample, triplicate reaction tubes with or
without 2 mM ouabain was processed. The reactions were
conducted for 3 h at 37°C. Inorganic phosphate was
determined by the colorimetric method (6). Na-K-ATPase
activities in the presence of patient IgG were compared
between patients with positive and negative antibodies for
both DCM and control subjects.
Western blots. Fifty micrograms of human cardiac mem-
brane was subjected to electrophoresis on a 10% polyacryl-
amide gel in SDS and transferred to nitrocellulose mem-
brane. Immunopurified IgG from each positive and negative
patients with DCM was used as primary antibodies and
were incubated overnight at 4°C. After the strips were
washed by TBST (10 mM Tris, 150 mM NaCl, 0.1%
Tween 20, pH 8), they were incubated with 1:1000 dilution
of rabbit anti-human IgG for 1 h at room temperature. The
specificity of the bands was checked by blocking effect of
porcine cerebral Na-K-ATPase after preincubation with
antibody overnight at 4°C. To further clarify the specific
bands, polyclonal antibody produced against Na-K-ATPase
catalytic subunit (LSL) were used in another experiment.
Radioligand binding assay. The ouabain-binding assay
was performed by the modified method described by Kim et
al. (13). Eighty micrograms of human cardiac membrane
was incubated in duplicate with six concentration (5 to 100
nmol/l) of [3H]ouabain (15 Ci/mmol; New England Nu-
clear) in the presence of either unlabeled ouabain (final
concentration 1 mmol/l) or vehicle at 37°C for 1 h. Each
reaction tube was added to 1 g of patient IgG. To separate
bound and unbound [3H]ouabain, the sample was filtered
through Whatman GF/C filters of 96-well UniFilter plates
by MicroMate cell harvester (Packard Japan Co.) followed
by washing with the distilled water. The filters were
measured for 3H radioactivity by Microplate Scintillation
Counter (TopCount, Packard Japan Co.). Specific binding
was defined as the difference between binding of
[3H]ouabain in the absence and presence of 1 mmol/l
unlabeled ouabain. 3H-ouabain binding sites were com-
pared between positive and negative IgG from patients with
DCM.
Clinical features of autoantibody (Ab)-positive pa-
tients. We compared age, gender, New York Heart Asso-
ciation functional class (NYHA), left ventricular ejection
fraction (LVEF) and other clinical parameters between
patients with or without the Na-K-ATPase Abs. Clinical
variables, including findings from ultrasonic echocardiogra-
phy and Holter monitoring, were recorded for all patients
Abbreviations and Acronyms
Ab/Abs  autoantibody/autoantibodies
CHF  congestive heart failure
DCM  dilated cardiomyopathy
ELISA  enzyme-linked immunosorbent assay
LVEF  left ventricular ejection fraction
NSVT  non-sustained ventricular tachycardia
NYHA  New York Heart Association
PNE  plasma norepinephrine
PVC  premature ventricular complex
VT  ventricular tachycardia
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within one month of serum sampling for measurement of
Abs. Echocardiography was performed using a commer-
cially available probe and system to assess left ventricular
end-diastolic dimensions, end-systolic dimensions and frac-
tional shortening. The Holter electrocardiogram (ECG)
was analyzed on a dual-channel by using the Marquette
system (SXP 8000 or MARS 8000) to assess the total
number of premature ventricular contractions (PVCs) and
occurrence of ventricular tachycardia (VT). Premature ven-
tricular contractions were defined as any beat of ventricular
origin faster than the sinus rate and VT as three or more
consecutive PVCs with a heart rate 100 beats/min, which
was noted in at least one of the tests. Data were averaged
from two or more sets of recordings. Blood samples for
measurement of serum potassium and digitalis concentra-
tion, plasma norepinephrine, renin and atrial natriuretic
peptide concentrations were collected from a peripheral vein
after the patient had rested in the supine position for at least
30 min. Blood samples were placed in ice and spun in a
refrigerated centrifuge to separate the plasma then stored at
80°C until analysis by adequate techniques.
Patient follow-up. The patients studied were followed for
a mean of 31 months (range 0.2 to 52.5 months). Deaths
were classified as follows: sudden death was defined as death
within 1 h without previous worsening of symptoms of heart
failure. Unexpected death occurring during sleep was con-
sidered to be sudden when patients were found dead in the
morning by family members sharing the same room. When
death occurred as a consequence of progressive deterioration
of heart failure, acute pulmonary edema or cardiogenic
shock, we classified it as a result of pump failure.
Statistical analyses. Data are expressed as the mean SD.
Optical densities of ELISA and enzyme activities and
radioligand binding assay of Na-K-ATPase were evaluated
using two-way repeated-measures analysis of variance
(ANOVA). For variables with p  0.05 regarding the effect
of interaction, we have analyzed the data among groups by
one-way ANOVA with Bonferroni post hoc test for mul-
tiple comparisons. In clinical features of patients, compari-
son between two groups was performed by using the
nonpaired two-tailed t test or the nonparametric means test
for continuous variables and by the chi-square test for
discrete variables. Logistic regression analysis was used to
assess predictors of VT. Ten variables, including those with
p values 0.10 by univariate analyses, were further assessed
by multivariate analysis. Kaplan-Meier survival curve for
cardiac sudden death was calculated according to presence
or absence of Abs, and the differences were analyzed by the
log-rank test. Long-term prognosis was assessed using the
Cox proportional hazards model. Statistical significance was
defined as p  0.05. StatView 5.0 software (SAS Institute
Inc.) was used for statistical analyses.
RESULTS
Enzyme-linked immunosorbent assay detected Abs pro-
duced against the Na-K-ATPase in 26 patients with DCM
and 2 control subjects in our study group. A substantial
reduction in optical densities was produced by dilution in
Figure 1. Enzyme-linked immunosorbent assay of autoantibodies pro-
duced against Na-K-ATPase in patients with dilated cardiomyopathy
(DCM). O.D.  optical density.
Figure 2. Na-K-ATPase enzyme activity incubated with purified IgG of
patients with dilated cardiomyopathy (DCM) and of CTL. *p  0.01.
Figure 3. Western blots of autoantibodies produced against alpha subunit
of Na-K-ATPase. (a) Immunopurified IgG of patients without autoanti-
bodies; (b) with autoantibodies; (c) preincubation of Na-K-ATPase with
(b), and (d) anti–Na-K-ATPase (alpha subunit) polyclonal antibodies.
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control subjects who were judged positive (data not shown)
but not in patients with DCM who were similarly positive
for Ab even in 1:160 dilution (Fig. 1).
Figure 2 shows activity of Na-K-ATPase from porcine
cerebral cortex in the presence of patient and control IgG
fractions. Na-K-ATPase activity was lower in the presence
of positive sera determined by ELISA than the presence of
negative sera in patients with DCM (48  16 vs. 79  19
M Pi/h/mg protein). There was no difference in the
activity between the two groups for control subjects (102 
22 vs. 99  21 M Pi/h/mg protein).
In Western blots analyses (Fig. 3), no band was detected
in the presence of negative IgG determined by ELISA from
patients with DCM. A single distinct band of approxi-
mately 110 kd was evident in the presence of positive IgG
determined by ELISA from patients with DCM. This band
was absorbed by preincubation with porcine Na-K-ATPase.
The molecular size was identical with that of the catalytic
alpha subunit of the enzyme.
In ouabain binding experiments, there was no difference
in the maximal binding sites between the presence of
positive and negative sera determined by ELISA (12.7 
1.8 vs. 15.3  1.8 pmol/mg protein). However, the disso-
ciation constant was higher in the presence of positive than
negative sera determined by ELISA (21.5  0.8 vs. 10.7 
0.7 nmol/l, p  0.01).
No differences existed in age, gender, NYHA functional
class, plasma potassium concentration, concomitant medi-
cations, including digitalis, and cardiac function between
patients with or without Abs. Furthermore, digitalis con-
Table 1. Patient Characteristics
Ab
Positive
Ab
Negative
Age 55  14 57  14
Gender (male/female) 20/6 57/17
NYHA functional class (I/II/III  IV) 14/8/4 38/27/9
Plasma potassium (mEq/l) 4.1  0.1 4.2  0.1
Concomitant medications
Digitalis glycosides 17/26 (65%) 45/74 (61%)
Digitalis concentration (ng/ml) 1.12  0.12 1.05  0.11
Diuretics 13/26 (50%) 42/74 (57%)
ACE inhibitors 13/26 (50%) 42/74 (57%)
Beta-blockers 7/26 (27%) 17/74 (23%)
Antiarrhythmic agents 6/26 (23%) 13/74 (18%)
Inotropic agents 2/26 (8%) 7/74 (9%)
Nitrates 3/26 (12%) 8/74 (11%)
Antiplatelet agents 8/26 (31%) 15/74 (20%)
Anticoagulants 11/26 (42%) 34/74 (46%)
LV ejection fraction (%) 31  10 30  10
LV end-diastolic diameter (mm) 61  10 60  10
LV end-systolic diameter (mm) 49  13 48  13
Fractional shortening (%) 20  11 21  10
Plasma renin activity (ng/ml/h) 8.5  9.8 6.7  7.9
Plasma ANP (pg/mL) 81  65 90  91
All values were similar between the two groups. Ab  autoantibody; ACE 
angiotensin-converting enzyme; ANP  atrial natriuretic peptide; NYHA  New
York Heart Association functional class; LV  Left ventricular.
Figure 4. Total number of PVCs and the prevalence of nonsustained ventricular tachycardia (NSVT) in patients with or without Na-K-ATPase
autoantibodies. *p  0.001.
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centration, plasma renin activity and atrial natriuretic pep-
tide concentration were similar between the two groups
(Table 1). However, the PNE concentration was signifi-
cantly higher in Ab-positive than in Ab-negative patients
(579  254 vs. 370  285 pg/ml, p  0.001). The
frequency of PVC on Holter monitoring was greater in
Ab-positive than in Ab-negative patients (3,505  4,482/
day vs. 1,669  4,601/day, p  0.001; Fig. 4). In addition,
multifocal PVC (100 vs. 68%, p  0.01) and nonsustained
VT (81% vs. 32%, p  0.001) were more common in
Ab-positive than in Ab-negative patients. Both the fre-
quency of VT (52  202/day vs. 45  62/day, p  0.05)
and the maximum length of runs of VT (11  8 vs. 7  5,
p  0.03) were greater in Ab-positive than in Ab-negative
patients. Univariate analyses were performed for 22 vari-
ables, including the PNE concentration, as well as for the
variables listed in Table 1, with the result that the presence
of Abs and PNE concentration was related to the presence
of VT. Multivariate logistic regression analyses were per-
formed for the 10 variables listed in Table 2, which showed
the presence of Abs, but not PNE concentration, to be the
only independent predictor of VT.
After a mean follow-up period of 31  15 months, 80
patients were alive. The 20 deaths included 11 sudden
deaths, 9 deaths resulting from pump failure, with no deaths
from unknown causes. Ten cardiac deaths occurred in
Ab-negative patients (four sudden deaths and six pump
failure deaths), and 10 cardiac deaths occurred in Ab-
positive patients (seven sudden deaths and three pump
failure deaths). Figure 5 compares the Kaplan-Meier sur-
vival curves for cardiac sudden death according to the
presence or absence of Abs. Sudden deaths were more
common among autoantibody-positive as compared with
Ab-negative patients. A Cox proportional hazards model
for cardiac sudden death was used to assess the significance
of Abs and other clinical variables in patients with DCM.
First, univariate analyses were performed for 20 variables,
including the presence of VT and each concomitant medi-
cation, as well as for the variables listed in Table 2. Eight
variables, including those with p  0.10 by univariate, were
further assessed by multivariate analysis (Table 3). The
presence of Abs and LVEF 21% were independent
predictors for cardiac sudden death.
DISCUSSION
Abs in idiopathic DCM. Several functional Abs have been
described in patients with DCM, including antibodies
against myosin (14), ADP/ATP transporter (15) and G-
protein–coupled receptors (12,16–18). We reported previ-
ously the frequency of antimyocardial Abs in patients with
DCM by either the method of standard indirect immuno-
fluorescence and immunoblotting (19). There were some
Table 2. Predictors of the Development of Ventricular
Tachycardia
Odds
ratio 95% CI p Value
Age 60 1.51 0.57–3.98 NS
Female gender 0.74 0.24–2.29 NS
NYHA II 1.64 0.65–4.10 NS
Plasma K  4.0 mmol/l 1.36 0.46–4.05 NS
LVEF 21% 3.72 0.73–19.06 NS
PVCs 1000/day 1.76 0.42–7.36 NS
PNE 713 pg/ml 1.01 0.20–5.25 NS
PRA 10 ng/ml/h 1.57 0.54–4.60 NS
ANP 100 pg/ml 1.31 0.46–3.75 NS
Na-K-ATPase antibodies 11.52 3.43–38.74  0.0001
ANP  atrial natriuretic peptide; LVEF  left ventricular ejection fraction; NS 
not significant; NYHA  New York Heart Association functional class; PNE 
plasma norepinephrine; PRA  plasma renin activity; PVCs  premature ventricular
complexes.
Figure 5. Kaplan-Meier survival curves for cardiac sudden death according to the presence or absence of autoantibodies.
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patients who had unknown Abs that were related to the
occurrence of arrhythmias. Particularly, the presence of a
110-kd autoantibody was significantly associated with the
risk of VT by multiple logistic regression analysis. Our
preliminary data by immunoscreening of human heart
cDNA library indicated that the Abs directed against
110-kd antigens reacted with sarcolemmal Na-K-ATPase
pump.
Na-K-ATPase in CHF. A number of studies have shown
that ouabain binding sites were decreased in the myocar-
dium of patients with CHF (5,20). The decrease in the
alpha-3 isoform expression of Na-K-ATPase was reported
in the setting of pacing-induced heart failure, with similar
alterations induced by the chronic administration of norepi-
nephrine (13). We also reported that Na-K-ATPase activity
was decreased in the erythrocyte membranes of patients
with CHF (6). A significant inverse correlation existed
between PNE and erythrocyte Na-K-ATPase activity, even
in the absence of digitalis glycosides. However, in some
patients with DCM, the Na-K-ATPase activity also was
decreased without an increase of PNE. These findings
suggested that other circulating substances might influence
the Na-K-ATPase activity in the pathophysiologic states of
DCM.
Anti–Na-K-ATPase antibodies. In the present study,
26% of patients with DCM and 2% of control subjects had
Abs produced against Na-K-ATPase by the ELISA
method, which have not been described previously. External
constant Na-K-ATPase activities in vitro were lower in the
presence of purified IgG from DCM patients with Abs than
without Abs. Therefore, this Ab (IgG) was biologically
active. In fact, Western blots using human myocardium
demonstrated that the Abs specifically target at the alpha
subunit of the enzyme. Furthermore, radioligand-binding
assay indicated surmountable antagonistic effect of Abs.
These results suggested that the autoantibodies bound the
catalytic subunit of Na-K-ATPase, resulting in a conforma-
tional change from a high-affinity to low-affinity state.
Preliminary data from our laboratory show that human
cardiac membranes immunoprecipitated by the Abs were
directed against the alpha3-, but not alpha1-, isoform of the
Na-K-ATPase.
Clinical features of patients with Abs. In the present
study, the presence of Abs produced against Na-K-ATPase
was associated with more frequent PVCs and nonsustained
VT, which appear to be mediated by non–re-entrant mech-
anism in patients with nonischemic heart failure (21).
Although the electrophysiologic function of the Abs is not
known, it is speculated that abnormal intracellular Ca2
handling by reduced Na-K-ATPase activity may cause
delayed afterdepolarizations via reverse-mode operation of
the Na/Ca2 exchanger resulting from increased intracel-
lular Na concentrations (22). Preliminary data using chick
embryonic ECGs (23) indicated that various ventricular
arrhythmias ranging from PVCs to VT, which were termi-
nated by verapamil, could be induced by affinity-purified
IgG from patients with the autoantibodies.
Conclusions. Functional Abs produced against Na-K-
ATPase may exert an arrhythmogenic effect via an autoim-
mune response in certain patients with DCM. Character-
ization of this Ab could be helpful in identifying patients
with electrical instability whom potentially susceptible to
sudden cardiac death.
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